Treatment Of Xanthelasma Palpebrarum With Bichloracetic Acid
Title
Treatment Of Xanthelasma Palpebrarum With Bichloracetic Acid
Creator
Haygood L J; Bennett J D; Brodell R T
Publisher
Dermatologic Surgery
Date
1998
1998-09
Description
BACKGROUND. Although many treatment modalities have been described for xanthelasma palpebrarum, no single technique has emerged as dominant. OBJECTIVES. Our purpose was to review the various therapeutic modalities for xanthelasma anti to assess the efficacy of topical bichloracetic acid. METHODS. Thirteen patients with 25 xanthelasma were treated with topical 100% bichloracetic acid. Efficacy was assessed over a follow-up period of 7 months to 10.5 years (average, 64 months). RESULTS. Eighty-five percent of patients experienced initial complete clearing, and 72% of their lesions have not required retreatment over an average period of 68 months. Recurrences responded well to repeat treatment. Eighty-three percent of recurrent or poorly responsive lesions were associated with high cholesterol. The most resistant patient had four-lid involvement. Excellent cosmetic results and high patient satisfaction were seen. CONCLUSIONS. Topical bichloracetic acid is a viable alternative to other modalities in the management of xanthelasma. Advantages include simplicity, cost-effectiveness, speed, safety, and efficacy. (C) 1998 by the American Society for Dermatologic Surgery, Inc.
Subject
co2-laser; Dermatology; dye-laser; lesions; Surgery
Identifier
Format
Journal Article or Conference Abstract Publication
Search for Full-text
Users with a NEOMED Library login can search for full-text journal articles at the following url: https://libraryguides.neomed.edu/home
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
1027-1031
Issue
9
Volume
24
Citation
Haygood L J; Bennett J D; Brodell R T, “Treatment Of Xanthelasma Palpebrarum With Bichloracetic Acid,” NEOMED Bibliography Database, accessed September 12, 2024, https://neomed.omeka.net/items/show/10138.